New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

December 17, 2020 -- The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

The vaccine candidate is currently being evaluated in a phase III clinical trial in the U.K. NVX-CoV2373 is a recombinant spike protein vaccine adjuvanted with Novavax's proprietary Matrix-M to enhance immune response.

Under the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021. The company will work with Medsafe, New Zealand's regulatory agency to obtain the necessary product approvals. Additional financial terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.